Principal Financial Group Inc. Has $47.13 Million Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Principal Financial Group Inc. decreased its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 5.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,645,051 shares of the specialty pharmaceutical company's stock after selling 100,767 shares during the period. Principal Financial Group Inc. owned approximately 5.10% of Collegium Pharmaceutical worth $47,132,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. CWM LLC grew its position in Collegium Pharmaceutical by 97.5% during the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company's stock worth $58,000 after buying an additional 736 shares during the period. Allspring Global Investments Holdings LLC grew its holdings in shares of Collegium Pharmaceutical by 83.5% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 79,822 shares of the specialty pharmaceutical company's stock worth $3,084,000 after acquiring an additional 36,331 shares during the period. Values First Advisors Inc. grew its holdings in shares of Collegium Pharmaceutical by 8.4% in the 3rd quarter. Values First Advisors Inc. now owns 18,412 shares of the specialty pharmaceutical company's stock worth $711,000 after acquiring an additional 1,419 shares during the period. Smith Group Asset Management LLC grew its holdings in Collegium Pharmaceutical by 25.1% in the third quarter. Smith Group Asset Management LLC now owns 18,824 shares of the specialty pharmaceutical company's stock valued at $727,000 after purchasing an additional 3,774 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Collegium Pharmaceutical by 61.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 6,196 shares of the specialty pharmaceutical company's stock valued at $239,000 after purchasing an additional 2,352 shares during the last quarter.

Analysts Set New Price Targets

Several analysts have recently commented on COLL shares. HC Wainwright reiterated a "buy" rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, January 10th. Needham & Company LLC upgraded Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 target price on the stock in a report on Friday, January 10th. Finally, Piper Sandler lowered their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating on the stock in a report on Tuesday, February 4th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $43.60.

Insider Activity at Collegium Pharmaceutical

In other news, EVP Shirley R. Kuhlmann sold 27,500 shares of the firm's stock in a transaction on Friday, January 10th. The shares were sold at an average price of $33.04, for a total value of $908,600.00. Following the transaction, the executive vice president now owns 119,184 shares of the company's stock, valued at approximately $3,937,839.36. This trade represents a 18.75 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 3.98% of the stock is owned by insiders.

Collegium Pharmaceutical Trading Down 2.1 %

Shares of COLL traded down $0.62 during mid-day trading on Friday, reaching $29.13. The company had a trading volume of 291,901 shares, compared to its average volume of 377,450. The stock has a market cap of $939.44 million, a price-to-earnings ratio of 12.56 and a beta of 0.82. The firm has a fifty day simple moving average of $30.98 and a 200-day simple moving average of $33.68. Collegium Pharmaceutical, Inc. has a fifty-two week low of $28.39 and a fifty-two week high of $42.29. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.